People · Operator
Named in public records as an officer, director or promoter · active 2017–2019 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Harmony Biosciences II, Inc. | — | Pharmaceuticals | Series D+ | $345.0M | $1.8B | 2017 |
DR. ANDREAS BECH WICKI at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside DR. ANDREAS BECH WICKI on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Antonio Gracias | 1 | 15 |
| Jack Nielsen | 1 | 13 |
| Aaron Royston | 1 | 7 |
| Patrick Morris | 1 | 6 |
| Jeffrey Aronin | 1 | 6 |
| Martin Edwards | 1 | 5 |
| Darien Parhad | 1 | 4 |
| Juan Sabater | 1 | 4 |
| JOHN JACOBS | 1 | 3 |
| Wilbur Gantz III | 1 | 1 |
| JACK BECH NIELSEN | 1 | 1 |
| MARTIN BECH EDWARDS | 1 | 1 |
| AARON BECH ROYSTON | 1 | 1 |
| WILBUR BECH GANTZ, III | 1 | 1 |
| JOHN VITTORIA | 1 | 1 |
| ANDREW SERAFIN | 1 | 1 |
| Dr. Andreas Wicki | 1 | 1 |
| Robert Repella | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.